Adaptive Biotechnologies shares fall as Natera's Foresight acquisition heightens MRD competition and tempers recent takeover speculation.

Adaptive Biotechnologies (ADPT) shares rallied 18% in the last trading session to close at $7.16. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

The biotech reported its second-quarter earnings just after market close the previous day. It topped analyst estimates on both the top and bottom lines. The commercial-stage Adaptive booked $58.9 ...

Adaptive Biotechnologies (ADPT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

The biotech reported its second-quarter earnings just after market close the previous day. It topped analyst estimates on both the top and bottom lines. These 10 stocks could mint the next wave of ...